NEW YORK, October 22, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding UnitedHealth Group Inc. (NYSE: UNH), Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), Bristol-Myers Squibb Company (NYSE: BMY) and Salix Pharmaceuticals Ltd. (NASDAQ: SLXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7391-100free.
--
UnitedHealth Group Inc. Research Reports
On October 17, 2014, UnitedHealth Group Inc.'s subsidiary UnitedHealthcare introduced a new Medicare Advantage plan - AARP MedicareComplete Focus (HMO), for beneficiaries in the Cincinnati area and Northern Kentucky. The new AARP MedicareComplete Focus (HMO) is designed to help people save money and enhance their health and well-being through additional benefits and health care services beyond those available with Original Medicare. UnitedHealthcare informed that more than 315,000 Medicare beneficiaries in Kentucky and Ohio can enroll for the plan during the open enrollment period - from October 15, 2014 to December 7, 2014. According to UnitedHealthcare, the plan has a $0 monthly premium beyond the Part B premium, and includes coverage of prescription drugs, a SilverSneakers fitness membership and UnitedHealthcare's Passport program. The full research reports on UnitedHealth are available to download free of charge at:
http://www.analystsreview.com/Oct-22-2014/UNH/report.pdf
--
Celgene Corporation Research Reports
On October 10, 2014, Celgene Corporation's wholly-owned subsidiary Celgene International Sàrl announced results of the ESTEEM phase III clinical trial program on additional efficacy and safety analyses of OTEZLA® (apremilast). The results were released at the 23rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam. Apremilast is the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), for patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. According to the Company, an analysis of ESTEEM 1 and 2 - the two large pivotal phase III randomized, placebo-controlled studies - found improvements in itching and in skin discomfort/pain with apremilast 30 mg twice daily were observed as early as week 2 and were maintained through week 32. The full research reports on Celgene are available to download free of charge at:
http://www.analystsreview.com/Oct-22-2014/CELG/report.pdf
--
Actavis plc Research Reports
On October 16, 2014, Actavis plc (Actavis) issued a press release to confirm that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Methylphenidate Hydrochloride for Extended-release Oral Suspension, 5 mg/mL- a generic version of Quillivant XR®. The announcement came a day after Tris Pharma Inc. (Tris Pharma) filed suit against Actavis in a U.S. district court seeking to prevent Actavis from marketing its generic version prior to the expiration of certain U.S. Patents. Actavis believes that it may be a "first applicant" to file an ANDA for the generic Quillivant XR and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity. Quillivant XR, a central nervous system stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder, had total U.S. sales of c.$52 million for the 12 months ended June 30, 2014, according to IMS Health data. The full research reports on Actavis are available to download free of charge at:
http://www.analystsreview.com/Oct-22-2014/ACT/report.pdf
--
Bristol-Myers Squibb Company Research Reports
On October 13, 2014, Bristol-Myers Squibb Company (Bristol-Myers Squibb) informed that it has entered into a clinical trial collaboration agreement with Pharmacyclics, Inc. (Pharmacyclics) and Janssen Research & Development, LLC (Janssen), to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb's investigational OPDIVO® (nivolumab) in combination with IMBRUVICA® (ibrutinib). OPDIVO is an investigational PD-1 immune checkpoint inhibitor, while IMBRUVICA is an oral Bruton's tyrosine kinase (BTK) inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). The full research reports on Bristol-Myers Squibb are available to download free of charge at:
http://www.analystsreview.com/Oct-22-2014/BMY/report.pdf
--
Salix Pharmaceuticals Ltd. Research Reports
On October 3, 2014, Salix Pharmaceuticals Ltd. (Salix) and Cosmo Pharmaceuticals S.p.A. (Cosmo) jointly announced that they have agreed to terminate their previously-announced merger agreement pursuant to which Salix would have become a wholly-owned subsidiary of Cosmo Technologies Limited, a subsidiary of Cosmo. As a result, Salix will make a $25 million payment to Cosmo. Salix's President and CEO, Carolyn Logan said, "When we announced our agreement to merge with Cosmo Technologies in July we believed the combination would generate significant value for our stockholders through the addition of key products to our development pipeline and a more efficient corporate structure that would enhance our profitability. Since then, however, the changed political environment has created more uncertainty regarding the potential benefits we expected to achieve. As a result, Salix and Cosmo have mutually agreed to terminate the proposed transaction. We look forward to a continuation of our long-standing relationship with Cosmo." The full research reports on Salix are available to download free of charge at:
http://www.analystsreview.com/Oct-22-2014/SLXP/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
